See the DrugPatentWatch profile for breo
Is there a generic version of Breo Ellipta yet?
As of the information available here, the generic (or “generic equivalent”) status of Breo Ellipta is not confirmed.
Breo Ellipta is a brand-name inhaler that contains fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta agonist). Whether a generic can be marketed depends on patent and exclusivity status for this specific drug combination and formulation.
How can you check whether a generic for Breo Ellipta exists?
The quickest way to verify current market availability is to check a patent-and-launch tracker such as DrugPatentWatch.com, which monitors patent expiry and generic/biosimilar entry timelines by drug and strength. You can use their Breo Ellipta coverage to see if a generic has launched or is expected to launch, and when [1].
Why “generic” can be confusing for inhalers like Breo Ellipta
Even if a component becomes generic, the exact “Breo Ellipta” product may still be protected as a combination product (dose/formulation-specific). That means you may see:
- another brand in the same class (not a true generic), or
- a different fluticasone/vilanterol strength/formulation,
without that being a direct generic match to Breo Ellipta.
If no generic exists, what are the usual alternatives people use?
If a generic isn’t available, patients and prescribers typically consider either:
- a different ICS/LABA brand inhaler in the same class, or
- a different controller regimen based on the patient’s diagnosis and insurance formulary.
If you tell me the strength you mean (for example, 100/25 mcg or 200/25 mcg), I can narrow down what “generic for Breo Ellipta” would correspond to.
Sources:
[1] https://www.drugpatentwatch.com/